Jefferies Financial Group Initiates Coverage on Vertex Pharmaceuticals (NASDAQ:VRTX)

Investment analysts at Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a report issued on Tuesday. The brokerage set a “buy” rating and a $580.00 price target on the pharmaceutical company’s stock. Jefferies Financial Group’s target price points to a potential upside of 25.85% from the company’s current price.

Several other brokerages have also recently commented on VRTX. UBS Group raised their target price on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Sanford C. Bernstein restated an “outperform” rating and set a $577.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $570.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Royal Bank Of Canada decreased their target price on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a research report on Friday, February 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $590.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $548.73.

Vertex Pharmaceuticals Trading Up 0.9%

VRTX opened at $460.87 on Tuesday. The stock’s fifty day simple moving average is $467.50 and its 200 day simple moving average is $435.79. The stock has a market cap of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31. Vertex Pharmaceuticals has a 1-year low of $362.50 and a 1-year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $3.98 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Charles F. Wagner, Jr. sold 9,532 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the completion of the transaction, the executive vice president owned 37,725 shares in the company, valued at approximately $17,391,225. This represents a 20.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Amit Sachdev sold 58,613 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $468.83, for a total value of $27,479,532.79. Following the sale, the executive vice president directly owned 58,934 shares in the company, valued at $27,630,027.22. This represents a 49.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 91,156 shares of company stock worth $42,845,497. 0.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Brighton Jones LLC increased its stake in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares in the last quarter. AE Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 112.0% in the second quarter. AE Wealth Management LLC now owns 2,468 shares of the pharmaceutical company’s stock worth $1,099,000 after purchasing an additional 1,304 shares in the last quarter. Midwest Trust Co acquired a new position in Vertex Pharmaceuticals in the second quarter valued at $254,000. PFG Advisors acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter worth about $207,000. Finally, Allworth Financial LP lifted its position in Vertex Pharmaceuticals by 77.9% in the 2nd quarter. Allworth Financial LP now owns 3,462 shares of the pharmaceutical company’s stock worth $1,541,000 after buying an additional 1,516 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER interim results met the primary and all secondary endpoints — Vertex reported strong Week 36 data showing povetacicept produced meaningful effects in adults with IgAN; the company described the readout as positive and the market reacted with after-hours buying. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Company and press reports say the data are strong enough that Vertex plans an FDA filing (reportedly by March) for povetacicept, and headlines emphasized a late-session/share pop — a clear near-term catalyst for upside if regulators agree on the path. Vertex (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results
• Positive Sentiment: Analysts reacted quickly: HC Wainwright raised its price target to $641 and kept a Buy rating; BMO Capital and William Blair reiterated Buy ratings with elevated targets (~$600 from BMO cited), reflecting expectations that povetacicept could be “best-in-class” in IgAN and add upside beyond Vertex’s cystic fibrosis cash flows. HC Wainwright price-target raise BMO / analyst coverage
• Neutral Sentiment: The RAINIER result cited is an interim analysis of an ongoing Phase 3 trial — strong interim data are encouraging but full trial readouts, regulatory review, and long-term safety/efficacy data remain to be confirmed. Investors should note the typical regulatory and commercialization execution risks. Yahoo Finance: Vertex interim analysis
• Negative Sentiment: Separately, Vertex’s most recent quarterly report showed a tiny EPS miss (reported 5.03 vs. 5.05 consensus) and, while revenue grew year-over-year, investors should weigh near-term valuation versus long-term pipeline upside. This older earnings miss could temper upside if pipeline approvals face delays. MarketBeat: VRTX profile / recent results

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.